Canton Strategic Holdings Inc., which was formerly known as Tharimmune, Inc. until its name change in February 2026, focuses on two primary areas. The company is committed to promoting the institutional integration of blockchain technology and fostering the digitization of financial markets, primarily by leveraging Canton Coin and offering support to the Canton network. In addition to its blockchain initiatives, the company is also deeply involved in pharmaceutical research and development. Its pipeline includes GV104, a buccal film technology designed to address respiratory and/or nervous…
| Price | $2.32 |
|---|---|
| Market cap | $178.54M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | NASDAQ |
| 52-week range | 1.75-6.89 |
| Beta | 1.5 |
Explore CNTN's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.